Lung cancer: open trials in India

• NCT07144280

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  Trial Treatment · Phase 3 · Pfizer

  Fortis Hospital, Delhi · Caritas Hospital, Kerala · Apollo Multispeciality Hospitals limited, Kolkata · Tata Memorial Hospital, Mumbai · Rajiv Gandhi Cancer Institute And Research Centre, New Delhi · Sahyadri Super Speciality Hospital, Pune

  Registry updated 2026-11-05

• NCT07361497

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  Trial Treatment · Phase 3 · Bristol-Myers Squibb

  Chhatrapati Sambhajinagar · Delhi · Dwarka · Eluru · Goraj · Hyderabad · Mumbai · Nagpur · New Delhi · Pūlakkōd · Pune

  Registry updated 2026-11-05

• NCT06119581

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  Trial Treatment · Phase 3 · Eli Lilly and Company

  Hemato Oncology Clinic, Ahmedabad · KLES Dr. Prabhakar Kore Hospital & M.R.C, Belagavi · SRV Hospitals, Bengaluru · All India Institute of Medical Sciences, Bhubaneswar · Ashwin Hospital, Coimbatore · Nizam's Institute of Medical Sciences, Hyderabad · Krishna Institute of Medical Sciences - Karad, Karad · Kolhapur Cancer Centre Private Limited, Kolhāpur · HCG Manavata Cancer Centre, Nashik · Advanced Centre for Treatment Research and Education in Cancer, Navi Mumbai · Jawaharlal Institute of postgraduate medical education and research, Puducherry · Sahyadri Super Speciality Hospital, Pune · Lifepoint Multispeciality Hospital, Pune · Grant Medical Foundation Ruby Hall Clinic, Pune · Regional Cancer Centre - Thiruvananthapuram, Thiruvananthapuram · Pacific Medical College & Hospital, Udaipur · Tata Memorial Centre - Homi Bhabha Cancer Hospital, Varanasi · Mahatma Gandhi Cancer Hospital and Research Institute, Visakhapatnam

  Registry updated 2026-11-04

• NCT06890598

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  Trial Treatment · Phase 3 · Eli Lilly and Company

  Hemato Oncology Clinic, Ahmedabad · Rajiv Gandhi Government General Hospital, Chennai · Galaxy Superspeciality Hospital, Chhatrapati Sambhajinagar · Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai · Thangam Cancer Center - Namakkal, Namakkal · Savera Cancer & Multi Speciality Hospital, Patna · Deenanath Mangeshkar Hospital & Research Centre, Pune · Medipoint Hospitals Pvt. Ltd., Pune · Malabar Cancer Centre - Thalassery, Thalassery · Regional Cancer Centre - Thiruvananthapuram, Thiruvananthapuram · Pacific Medical College & Hospital, Udaipur · Tata Memorial Centre - Homi Bhabha Cancer Hospital, Varanasi

  Registry updated 2026-11-04

• NCT04613596

  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  Trial Treatment · Phase 2/3 · Mirati Therapeutics Inc.

  CIMS Hospital, Ahemdabad · Local Institution - 007-1574, Ahmedabad · Local Institution - 007-1586, Bangalore · KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Belagavi · Marathwada Cancer Hospital & Research Institute, Chhatrapati Sambhajinagar · Local Institution - 007-1587, Howrah · Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad · Local Institution - 007-1564, Hyderabad · Local Institution - 007-1569, Jaipur · Amrita Institute of Medical Sciences & Research Centre, Kochi · Netaji Subhas Chandra Bose Cancer Hospital, Kolkata · Meenakshi Mission Hospital and Research Centre, Madurai · Local Institution - Shetty, R., Mangalore · Tata Memorial Centre - Tata Memorial Hospital, Mumbai · Mysore Medical College and Research Institute, Mysore · Local Institution - 007-1578, New Delhi · Local Institution - 007-1588, New Delhi · Indraprastha Apollo Hospitals, New Delhi · Indira Gandhi Institute of Medical Sciences, Patna · Local Institution - 007-1571, Pune · Nirmal Hospital Pvt. Ltd., Rajkot · Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi

  Registry updated 2026-10-30

• NCT06692738

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  Trial Treatment · Phase 3 · AstraZeneca

  Calicut · Delhi · Gūrgaon · Kolkata · Madurai · Mumbai · Nagpur · Nashik · New Delhi · Puducherry · Surat · Varanasi

  Registry updated 2026-10-29

• NCT06357533

  Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  Trial Treatment · Phase 3 · AstraZeneca

  Chennai · Dwārka · Jaipur · Kolkata · Marg Jaipur · Nagpur · Nashik · New Delhi · Surat · Thiruvananthapuram

  Registry updated 2026-10-28

• NCT06627647

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  Trial Treatment · Phase 3 · AstraZeneca

  Calicut · Delhi · Gūrgaon · Kolkata · Madurai · Mumbai · Nashik · New Delhi · Varanasi

  Registry updated 2026-10-28

• NCT06875310

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  Trial Treatment · Phase 3 · Mirati Therapeutics Inc.

  Marengo CIMS Hospital, Ahmedabad · Hemato Oncology Clinic, Ahmedabad · Institute of Medical Sciences and Sum Hospital, Bhubaneswar · Narayana Superspecialty Hospital, Howrah · Yashoda Hospitals - Hitech City, Hyderabad · Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad · Netaji Subhas Chandra Bose Cancer Hospital, Kolkata · Meenakshi Mission Hospital and Research Centre, Madurai · Mumbai · Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi · Rajiv Gandhi Cancer Institute And Research Centre, New Delhi · All India Institute of Medical Sciences, New Delhi · Thiruvananthapuram · Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi · Apollo Hospitals - Visakhapatnam - Health City, Visakhapatnam

  Registry updated 2026-10-27

• NCT06345729

  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Sir H. N. Reliance Foundation Hospital and Research Centre (Site 3201), Mumbai · Tata Memorial Hospital (Site 3205), Mumbai · Indraprastha Apollo Hospitals-APOLLO RESEARCH INNOVATION (Site 3203), New Delhi · AIIMS New Delhi Dept of Medicine (Site 3206), New Delhi

  Registry updated 2026-10-26

• NCT07680790

  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  Trial Treatment · Phase 3 · Bristol-Myers Squibb

  Badsa · Belagavi · Chennai · Gurgaon · Mohali · Pune · Vadodara

  Registry updated 2026-10-26

• NCT06561386

  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  Trial Treatment · Phase 3 · Bristol-Myers Squibb

  Badsa · Manipal Hospitals, Bengaluru · Narayana Superspecialty Hospital, Howrah · Tata Memorial Hospital, Mumbai · Mumbai Oncocare Centre Vile Parle, Mumbai · Rajiv Gandhi Cancer Institute And Research Centre, New Delhi · New Delhi · All India Institute of Medical Sciences, New Delhi · Yashoda Hospital, Secunderabad · Regional Cancer Centre - Thiruvananthapuram, Thiruvananthapuram · Varanasi

  Registry updated 2026-10-23

• NCT06899126

  Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  Trial Treatment · Phase 3 · Daiichi Sankyo

  Mazumdar Shaw Medical Center, Bangalore · All India Institute of Medical Sciences, Bhubaneswar · Narayana Superspeciality Hospital, Howrah · Yenepoya Medical College Hospital, Mangalore · Deenanath Mangeshkar Hospital and Research Centre, Pune · Nirmal Hospital Private Limited, Surat

  Registry updated 2026-10-23

• NCT07063745

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  Trial Treatment · Phase 2/3 · Bristol-Myers Squibb

  Aster CMI Hospital, Bangalore · Bengaluru · Apollo Hospitals, Hyderabad · Mumbai · Mumbai · Nashik · New Delhi · Varanasi

  Registry updated 2026-10-23

• NCT07361510

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  Trial Treatment · Phase 3 · Bristol-Myers Squibb

  Delhi · Dwarka · Goraj · Hyderabad · Mumbai · Mumbai · Nagpur · Pune · Visakhapatnam

  Registry updated 2026-10-23

• NCT06646276

  A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

  Trial Treatment · Phase 3 · Bristol-Myers Squibb

  Bengaluru · Kolkata · Madurai · New Delhi · Varanasi

  Registry updated 2026-10-13

• NCT07291037

  Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  Trial Treatment · Phase 3 · AstraZeneca

  Bangalore · Kolkata · Mumbai · Nashik · New Delhi

  Registry updated 2026-10-13

• NCT07100080

  Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  Trial Treatment · Phase 2/3 · Bristol-Myers Squibb

  Ahmedabad · Ahmedabad · Bengaluru · Gurugram · Howrah · Mumbai · Mumbai · Nagpur · New Delhi

  Registry updated 2026-10-09

• NCT07476287

  Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

  Trial Treatment · Phase 2 · Pfizer

  Caritas Hospital and Institute of Health Sciences, Kottayam · Rajiv Gandhi Cancer Institute And Research Centre, New Delhi

  Registry updated 2026-10-09

• NCT07222566

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  Trial Treatment · Phase 3 · Pfizer

  Radhakrishna Multispecialty Hospital & IVF Centre, Bangalore · KLES Dr. Prabhakar Kore Hospital & M.R.C, Belagavi · Sparsh Hospitals & Critical Care (P) Ltd, Bhubaneswar · Artemis Hospital, Gurugram · Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad · Chittaranjan National Cancer Institute, Kolkata · Caritas Hospital, Kottayam · National Cancer Institute, Nagpur · Apex Wellness Hospital, Nashik · Fortis Hospital, New Delhi · Rajiv Gandhi Cancer Institute And Research Centre, North West Delhi · Sahyadri Super Speciality Hospital, Pune · Nirmal Hospital Pvt Ltd., Surat · Bhakti Vedanta Hospital and Research Institute, Thane · Kailash Cancer Hospital & Research Centre, Vadodara

  Registry updated 2026-10-08

• NCT07822880

  A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India

  Trial Treatment · Phase 4 · Eli Lilly and Company

  The Gujarat Cancer & Research Institute (GCRI), Ahmedabad · SRV Hospitals, Bengaluru · AIIMS, Bhubaneshwar, Bhubaneswar · Aadhar Health Institute, Hisar · Ruby General Hospital Pvt. Ltd, Kolkata · Government Medical College, Kozhikode, Kozhikode · Mumbai Oncocare Center, Mumbai (E) · Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi · Institute Rotary Cancer Hospital, New Delhi · MPMMCC(Mahamana Cancer Hospital), Varanasi

  Registry updated 2026-10-08

• NCT06758401

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  Trial Treatment · Phase 3 · Pfizer

  Spandana Oncology Centre (SOC), Bengaluru · AIG Hospitals, Hyderabad · Tata Memorial Hospital, Mumbai · Dr B. L. Kapur Memorial Hospital, New Delhi · Venkateshwar Hospital, New Delhi · Fortis Hospital, New Delhi · Sahyadri Super Speciality Hospital, Pune · Bhakti Vedanta Hospital and Research Institute, Thane

  Registry updated 2026-09-25

• NCT07565987

  The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer

  Trial Treatment · All India Institute of Medical Sciences

  Nci, Aiims-Jhajjar, Jhajjar

  Registry updated 2026-09-24

• NCT06350097

  Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

  Trial Treatment · Phase 3 · AstraZeneca

  Bangalore · Delhi · Hyderabad · Kolkata · Mysuru · Nagpur · Nashik · New Delhi · Vadodara · Varanasi

  Registry updated 2026-08-26

• NCT07755397

  First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor

  Trial Treatment · Phase 1 · Jubilant Therapeutics India Limited

  Oncoville Cancer Hospital and Research Center, Bangalore · Tata Memorial Center, Mumbai · HCG Manavata Cancer Centre, Nashik · All India Institute of Medical Sciences(AIIMS), New Delhi · Kiran Super Multi-Speciality Hospital, Surat · SunAct Cancer Institute Pvt Ltd, Thane

  Registry updated 2026-08-10

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error